JP2025165975A5 - - Google Patents
Info
- Publication number
- JP2025165975A5 JP2025165975A5 JP2025120662A JP2025120662A JP2025165975A5 JP 2025165975 A5 JP2025165975 A5 JP 2025165975A5 JP 2025120662 A JP2025120662 A JP 2025120662A JP 2025120662 A JP2025120662 A JP 2025120662A JP 2025165975 A5 JP2025165975 A5 JP 2025165975A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- acceptable salt
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19184015.6 | 2019-07-02 | ||
| EP19184015 | 2019-07-02 | ||
| PCT/EP2020/068386 WO2021001360A1 (en) | 2019-07-02 | 2020-06-30 | Prostate specific membrane antigen (psma) ligands and uses thereof |
| JP2021578240A JP7805170B2 (ja) | 2019-07-02 | 2020-06-30 | 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021578240A Division JP7805170B2 (ja) | 2019-07-02 | 2020-06-30 | 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025165975A JP2025165975A (ja) | 2025-11-05 |
| JP2025165975A5 true JP2025165975A5 (enExample) | 2026-02-13 |
Family
ID=67145647
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021578240A Active JP7805170B2 (ja) | 2019-07-02 | 2020-06-30 | 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用 |
| JP2025120662A Pending JP2025165975A (ja) | 2019-07-02 | 2025-07-17 | 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021578240A Active JP7805170B2 (ja) | 2019-07-02 | 2020-06-30 | 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230226227A1 (enExample) |
| EP (1) | EP3993837A1 (enExample) |
| JP (2) | JP7805170B2 (enExample) |
| KR (1) | KR20220044496A (enExample) |
| CN (3) | CN120441497A (enExample) |
| AR (1) | AR119331A1 (enExample) |
| AU (3) | AU2020299974A1 (enExample) |
| BR (1) | BR112021026812A2 (enExample) |
| CA (1) | CA3144557A1 (enExample) |
| CL (1) | CL2021003525A1 (enExample) |
| CO (1) | CO2021017708A2 (enExample) |
| IL (1) | IL289039A (enExample) |
| MX (1) | MX2022000136A (enExample) |
| PH (1) | PH12021553284A1 (enExample) |
| TW (1) | TW202114742A (enExample) |
| WO (1) | WO2021001360A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021219719A1 (en) * | 2020-04-29 | 2021-11-04 | Advanced Accelerator Applications (Italy) Srl | Methods for radiolabelling psma binding ligands and their kits |
| CN121604981A (zh) | 2023-07-21 | 2026-03-03 | 诺华公司 | 靶向psma的放射性配体治疗方案 |
| WO2025125469A1 (en) | 2023-12-13 | 2025-06-19 | Swiss Rockets Ag | Combination therapy using psma-targeted radiopharmaceuticals and an inhibitor of pi3k, akt, and/or mtor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001271026A1 (en) | 2000-07-11 | 2002-01-21 | Bml, Inc. | Remedies for bone diseases |
| HUE045028T2 (hu) * | 2011-08-05 | 2019-12-30 | Molecular Insight Pharm Inc | Radiojelzett prosztataspecifikus membrán antigén inhibitorok |
| GEP20237479B (en) * | 2013-10-18 | 2023-03-27 | Deutsches Krebsforsch | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| KR20250057132A (ko) | 2016-03-22 | 2025-04-28 | 더 존스 홉킨스 유니버시티 | 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제 |
| US11478558B2 (en) * | 2017-05-30 | 2022-10-25 | The Johns Hopkins University | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
| IL276528B2 (en) * | 2018-02-06 | 2024-11-01 | Univ Johns Hopkins | PSMA Targeted Radiohalogenated Urea-Polyaminocarboxylates For Cancer Radiotherapy |
| WO2020028323A1 (en) * | 2018-07-30 | 2020-02-06 | The Johns Hopkins Universtiy | Competitive prostate-specific membrane antigen (psma) binding agents for the reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy |
-
2020
- 2020-06-30 MX MX2022000136A patent/MX2022000136A/es unknown
- 2020-06-30 JP JP2021578240A patent/JP7805170B2/ja active Active
- 2020-06-30 PH PH1/2021/553284A patent/PH12021553284A1/en unknown
- 2020-06-30 US US17/622,060 patent/US20230226227A1/en active Pending
- 2020-06-30 EP EP20734426.8A patent/EP3993837A1/en active Pending
- 2020-06-30 WO PCT/EP2020/068386 patent/WO2021001360A1/en not_active Ceased
- 2020-06-30 CA CA3144557A patent/CA3144557A1/en active Pending
- 2020-06-30 KR KR1020227003148A patent/KR20220044496A/ko active Pending
- 2020-06-30 AU AU2020299974A patent/AU2020299974A1/en not_active Abandoned
- 2020-06-30 CN CN202510573851.3A patent/CN120441497A/zh active Pending
- 2020-06-30 CN CN202080047295.1A patent/CN114341118A/zh active Pending
- 2020-06-30 CN CN202510573926.8A patent/CN120441498A/zh active Pending
- 2020-06-30 BR BR112021026812A patent/BR112021026812A2/pt unknown
- 2020-07-01 AR ARP200101868A patent/AR119331A1/es unknown
- 2020-07-02 TW TW109122386A patent/TW202114742A/zh unknown
-
2021
- 2021-12-15 IL IL289039A patent/IL289039A/en unknown
- 2021-12-23 CO CONC2021/0017708A patent/CO2021017708A2/es unknown
- 2021-12-28 CL CL2021003525A patent/CL2021003525A1/es unknown
-
2024
- 2024-02-09 AU AU2024200850A patent/AU2024200850B2/en active Active
-
2025
- 2025-07-17 JP JP2025120662A patent/JP2025165975A/ja active Pending
- 2025-11-24 AU AU2025271182A patent/AU2025271182A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025165975A5 (enExample) | ||
| EP2648766B1 (en) | Psma-targeted dendrimers | |
| EP0587555B1 (en) | A bifunctional dtpa-type ligand | |
| CN117563022A (zh) | 可用于成像和抗肿瘤治疗的具有可调的药代动力学的三功能构建体 | |
| JP4948742B2 (ja) | ペプチド系化合物 | |
| RU2156774C2 (ru) | Соматостатиновые пептиды, радиофармацевтическое средство, способ лечения опухолей, фармацевтический состав | |
| KR20080103562A (ko) | 치환된 방향족 잔기 및 그의 유도체를 갖는 킬레이팅 컨쥬게이트 | |
| CN108290924A (zh) | 肽硫脲衍生物、含有其的放射性同位素标记化合物、和含有该化合物作为活性成分的用于治疗或诊断前列腺癌的药物组合物 | |
| JP2025165975A (ja) | 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用 | |
| CN112870389A (zh) | 一种与放射性金属复合的DZ-1-Lys-DOTA偶联物及应用 | |
| WO2024193724A1 (zh) | 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂 | |
| KR20080099279A (ko) | 이관능성 레조르시놀, 티오레조르시놀, 및 디티오레조르시놀 유도체 금속 킬레이팅 컨쥬게이트 | |
| CN118647415A (zh) | 包含225锕标记的络合物和铋多价螯合剂的药物组合物 | |
| EP0630264A4 (en) | LIGANDS TO IMPROVE METAL CHELATE-GENERATION KINETICS. | |
| ES2898708T3 (es) | Ligandos macrocíclicos lipófilos, sus complejos, así como sus usos médicos | |
| CZ20014603A3 (cs) | Pouľití aminopolykarboxylátových ligandů při značení biologicky aktivních substrátů Tc-99m-trikarbonylovými prekurzory | |
| JPH08508048A (ja) | リガンド及びその金属錯体 | |
| JP7608378B2 (ja) | 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用 | |
| RU2022102061A (ru) | Лиганды простат-специфического мембранного антигена (psma) и варианты их применения | |
| RU2366434C1 (ru) | Гексаядерные кластерные комплексы рения на основе радиоактивных изотопов, обладающие противоопухолевыми свойствами | |
| CN119101130A (zh) | 一种用于诊断和治疗高表达cxcr4癌症的靶向剂 | |
| EP4568712A1 (en) | Dimeric radiopharmaceuticals, compositions thereof and uses thereof | |
| WO2025153101A1 (zh) | 一种含氮化合物及其制备方法与用途 | |
| CN121550453A (zh) | Pd-l1靶向的放射性多肽探针及其制备方法和应用 | |
| JP2001518524A (ja) | 放射線イメージング剤又は放射線防護剤の送達の強化 |